News stories about Five Prime Therapeutics (NASDAQ:FPRX) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Five Prime Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.3059590004814 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Hot Stock’s Trend Recap – Five Prime Therapeutics, Inc. (NASDAQ: FPRX) – The Investor Guide (wallstreetnews24.com)
- Five Prime Therapeutics, Inc. (NASDAQ:FPRX) – Hot Mover of the Day – Nasdaq Journal (press release) (nasdaqjournal.com)
- Five Prime Therapeutics (FPRX) Upgraded at BidaskClub (americanbankingnews.com)
- BRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement (reuters.com)
- Investor’s Roundup (Volatility in Focus) – Five Prime Therapeutics, Inc., (NASDAQ: FPRX) – Stock Watch (stocksnewstimes.com)
Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target for the company in a report on Monday, October 16th. Royal Bank of Canada upped their price target on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, November 6th. BMO Capital Markets upped their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, November 7th. Jefferies Group reiterated a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $64.00.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The company had revenue of $8.33 million for the quarter, compared to the consensus estimate of $16.16 million. During the same quarter last year, the company posted ($0.72) EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. equities analysts expect that Five Prime Therapeutics will post -5.56 earnings per share for the current fiscal year.
In other Five Prime Therapeutics news, Director William R. Ringo sold 600 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the transaction, the director now owns 600 shares of the company’s stock, valued at $27,198. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares in the company, valued at approximately $48,312. The disclosure for this sale can be found here. In the last three months, insiders sold 4,400 shares of company stock worth $175,666. Insiders own 6.50% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.